PWPS
MBRX icon

Pinnacle Wealth Planning Services’s Moleculin Biotech MBRX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$643 Hold
281
– – ﹤0.01% 2602
2025
Q4 		$930 Buy
+281
New +$2.62K ﹤0.01% 2596

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Pinnacle Wealth Planning Services's MBRX Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its Moleculin Biotech (MBRX) position steady in Q1 2026 at 281 shares worth $643. The position accounts for ﹤0.01% of the portfolio, ranked #2602.

Pinnacle Wealth Planning Services first reported a position in MBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $930 in Q4 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Pinnacle Wealth Planning Services held 281 shares of Moleculin Biotech worth $643 as of Q1 2026.
  • Pinnacle Wealth Planning Services left its Moleculin Biotech share count unchanged in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2602 holding.
  • Pinnacle Wealth Planning Services first reported a position in Moleculin Biotech in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's Moleculin Biotech position peaked at $930 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.